Alliance for Pandemic Preparedness

January 28, 2021

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Category:

Topic:

Keywords (Tags): ,

[Press release, not peer-reviewed] Preliminary results for phase 2/3 trials for the recombinant protein-based COVID-19 vaccine NVX-CoV2373 made by Novavax showed up to 89.3% efficacy in the UK cohort (n= >15,000), where 56 participants in the placebo group developed COVID-19 vs 6 in the vaccine group. Of note, the B.1.1.7 variant was observed in 32 of the COVID-19 cases, yielding an estimate of 85.6% efficacy against the variant.

Preliminary results from the South Africa cohort (n= >4,400) showed efficacy of 60% in the HIV-negative study population vs. 49.4% in the overall study population, with 29 COVID-19 cases observed in the placebo group vs. 15 in the vaccine group. Among 27 of the 44 cases with sequence data, mutations consistent with the B.1.351 variant were detected in 25 (93%).

Approximately 1/3 of patients in the South Africa cohort (but not included in the preliminary results) were seropositive at baseline, indicating prior COVID-19 infection. 

Novavax. (Jan 28, 2021). Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Press release downloaded Jan 28 from https://ir.novavax.com/node/15506/pdf